Run With Purpose. Give With Heart.
December 28, 2022
On November 5, 2023 - Runners will take on the marathon to support Charcot-Marie-Tooth Disease research.
News & Stories
News from the Hereditary Neuropathy Foundation: research updates, clinical trial progress, partnerships, and advocacy wins for the Charcot-Marie-Tooth community.
No matches for .
Showing 85 to 96 of 153 in News
-
-
Can Existing Drugs Treat CMT?
October 13, 2022
HNF, in partnership with Rarebase, is leading the charge in the first-ever research initiative to tackle multiple types of CMT in one project using its tech-enabled drug discovery platform called "Function."
-
SORD Webinar - Part 2 - Clinical Trial Update
October 9, 2022
Clinical Trial Update for SORD Deficiency - Applied Therapeutics - Dr. Shoshana Shendelman
-
Battersby Lab Donor Story: Fighter Moms Donate to Vital Research into Mitochondrial Diseases
October 4, 2022
Battersby Lab Donor Story Fighter Moms Donate to Vital Research into Mitochondrial Diseases
-
The Key Role CMT Patients Play in Research
September 16, 2022
Without your participation, researchers won’t have the essential patient information to develop drugs, gene therapies, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies. In addition, as GRIN grows, we gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies.
-
What is SORD Deficiency?
September 11, 2022
Could you be 1 of the estimated 3300 patients in the US with the gene causing SORD Deficiency?
-
How to get genetic Testing: The CMT Genie
September 10, 2022
Trying to get a genetic confirmation of CMT can be overwhelming, and you might not have access to healthcare providers who are familiar with all the choices out there.
-
SORD INSPIRE Phase III Clinical Trial
September 9, 2022
HNF Partner Applied Therapeutics is Currently Enrolling SORD Deficiency Patients for the INSPIRE Phase III Clinical Trial
-
The Future of CMT Research
August 13, 2022
Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or research.
-
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
April 29, 2022
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
-
3 New CMT Drug Development Projects
April 11, 2022
HNF Announces 3 New Drug Partnerships & Pathways Targeting Multiple Forms of CMT.
-
What is SORD Deficiency: Part 2
March 11, 2022
Join us for this webinar as we learn more about Sorbitol Dehydrogenase (SORD) Deficiency
